U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.086
Optical Activity ( + / - )
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IFOSFAMIDE

SMILES

ClCCNP1(=O)OCCCN1CCCl

InChI

InChIKey=HOMGKSMUEGBAAB-UHFFFAOYSA-N
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

HIDE SMILES / InChI
Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.086
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ifosfamide (IF) is a widely used antitumor prodrug. It is in the oxazaphosphorine class of alkylating agents, and it is effective against solid tumors. Ifosfamide mechanism of crosslinking DNA plays a major role in preventing cancer cells from proliferating. Ifosfamide is approved by FDA for the treatment of germ cell testicular cancer.

CNS Activity

CNS Active
4002
Curator's Comment: Ifosfamide crosses the blood-brain barrier and may cause encephalopathy.

Originator

Approval Year

1987
121
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
83
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
IFEX

Approved Use

Ifosfamide injection, used in combination with certain other approved antineoplastic agents, is indicated for third line chemotherapy of germ cell testicular cancer. It should be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna.

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
346 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9528844
3 g/m² single, intravenous
dose: 3 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
200 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, oral
dose: 1.5 g/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
203 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, intravenous
dose: 1.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2197 mM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9528844
3 g/m² single, intravenous
dose: 3 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1360 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, oral
dose: 1.5 g/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1520 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, intravenous
dose: 1.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.54 mM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8339288
3 g/m² 1 times / day multiple, intravenous
dose: 3 g/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.33 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9528844
3 g/m² single, intravenous
dose: 3 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, oral
dose: 1.5 g/m²
route of administration: Oral
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.6 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1795004
1.5 g/m² single, intravenous
dose: 1.5 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.12 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8339288
3 g/m² 1 times / day multiple, intravenous
dose: 3 g/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
IFOSFAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
unknown
 IFOSFAMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
18 g/m2 1 times / day multiple, intravenous
MTD
Dose: 18 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
DLT: Neutropenia, Infection...
Dose limiting toxicities:
Neutropenia (grade 4, 83.3%)
Infection (severe, 33.3%)
Thrombocytopenia (grade 4, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
2.25 g/m2 1 times / day multiple, intravenous
MTD
Dose: 2.25 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.25 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
DLT: Neutropenia, Febrile neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 66.7%)
Febrile neutropenia (grade 5, 33.3%)
Thrombocytopenia (grade 4, 66.7%)
Anemia (grade 4, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
1.2 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.2 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 g/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
Disc. AE: Nephrotoxicity, Renal failure...
AEs leading to
discontinuation/dose reduction:
Nephrotoxicity (severe)
Renal failure (severe)
Cystitis hemorrhagic (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Thrombocytopenia grade 4, 66.7%
DLT
18 g/m2 1 times / day multiple, intravenous
MTD
Dose: 18 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
Neutropenia grade 4, 83.3%
DLT
18 g/m2 1 times / day multiple, intravenous
MTD
Dose: 18 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
Infection severe, 33.3%
DLT
18 g/m2 1 times / day multiple, intravenous
MTD
Dose: 18 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/10572607
Anemia grade 4, 66.7%
DLT
2.25 g/m2 1 times / day multiple, intravenous
MTD
Dose: 2.25 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.25 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
Neutropenia grade 4, 66.7%
DLT
2.25 g/m2 1 times / day multiple, intravenous
MTD
Dose: 2.25 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.25 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
Thrombocytopenia grade 4, 66.7%
DLT
2.25 g/m2 1 times / day multiple, intravenous
MTD
Dose: 2.25 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.25 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
Febrile neutropenia grade 5, 33.3%
DLT, Disc. AE
2.25 g/m2 1 times / day multiple, intravenous
MTD
Dose: 2.25 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.25 g/m2, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11840607
Cystitis hemorrhagic severe
Disc. AE
1.2 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.2 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 g/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
Nephrotoxicity severe
Disc. AE
1.2 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.2 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 g/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
Renal failure severe
Disc. AE
1.2 g/m2 1 times / day multiple, intravenous
Recommended
Dose: 1.2 g/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 1.2 g/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inducer
1087
substrate
1193

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2B6
776

CYP3A5
446

CYP2B1
12

CYP2C19
1119

CYP2A6
626

CYP2C8
810

UGT
219

alcohol dehydrogenase
7

ALDH1
3

P-gp
2052

OCT2
434

OAT1
395

OAT3
391

MRP1
113
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 yes
PXR
51
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT1
395
 no
OAT3
391
 no
P-gp
2052
 no
CYP2C9
1193
 poor
ALDH1
3
 yes
Aldoifosfamide
3
CYP2A6
626
 yes
CYP2B1
12
 yes
CYP2C19
1119
 yes
CYP2C8
810
 yes
CYP3A5
446
 yes
MRP1
113
 yes
OCT2
434
 yes
UGT
219
 yes
4-HYDROXYIFOSFAMIDE
3
alcohol dehydrogenase
7
 yes
4-HYDROXYIFOSFAMIDE
3
CYP2B6
776
 yes
no (co-administration study)
Comment: Coadministration of ifosfamide with ketoconazole or rifampin did not produce changes inthe pharmacokinetics of the parent or metabolites that may result in an increased benefit of ifosfamidetherapy. (https://pubmed.ncbi.nlm.nih.gov/11503007/)
Page: 28.0
CYP3A4
1946
 yes
no (co-administration study)
Comment: Coadministration of ifosfamide with ketoconazole or rifampin did not produce changes inthe pharmacokinetics of the parent or metabolites that may result in an increased benefit of ifosfamidetherapy. (https://pubmed.ncbi.nlm.nih.gov/11503007/)
Page: 28.0
PubMed

PubMed

TitleDatePubMed
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
2007-08
High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.
2001-06-01
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
2001-06
Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors.
2001-06
A preclinical model for experimental chemotherapy of human head and neck cancer.
2001-06
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
2001-05-19
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
2001-05-01
Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
2001-05
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
2001-05
Haemoperfusion combined with haemodialysis in ifosfamide intoxication.
2001-05
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
2001-05
Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease.
2001-04-01
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
2001-04-01
Salvage chemotherapy in relapsed germ cell tumors.
2001-04
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
2001-04
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
2001-04
[Pigmented villonodular synovitis: apropos of 3 cases].
2001-04
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
2001-04
Modified dorsalis pedis flap for coverage of a pretibial pressure sore after hip rotationplasty.
2001-04
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
2001-03-15
Tumor oxygenation after radiotherapy, chemotherapy, and/or hyperthermia predicts tumor free survival.
2001-03-15
Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor.
2001-03
[Surgical treatment of non-small cell lung cancer with mediastinal node invasion. A retrospective study].
2001-03
Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
2001-03
Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
2001-03
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
2001-03
Gemcitabine for the treatment of non-small-cell lung cancer.
2001-03
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
2001-03
Intrasellar rhabdomyosarcoma: case report.
2001-03
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine].
2001-03
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
2001-03
Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report.
2001-03
The current status of docetaxel for advanced non-small cell lung cancer.
2001-02
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
2001-02
Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.
2001-02
Chemotherapy agents in transitional cell carcinoma: the old and the new.
2001-02
PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.
2001-02
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
2001-02
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
2001-02
[Addisonian crisis as first manifestation of adrenal gland insufficiency in patient diagnosed with lung cancer].
2001-01
[Prostatic angiosarcoma: report of a new case].
2001-01
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
2001-01
Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials.
2001
A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer.
2001
The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.
2001
Malignant mixed mullerian tumor of the ovary: report of four cases.
2001
Treatment of ruptured undifferentiated sarcoma of the liver in children: a report of two cases and review of the literature.
2001
Carnitine protects mitochondria and removes toxic acyls from xenobiotics.
2001
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
2001
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
2001
Patents

Patents

04929607
3
20110251159
6
6197760
3
8507464
4
JP2002511777A
420
JP2003529540A
50
JP2006528196A
42
JP2007507506A
3
JP2008510829A
14
JP2008519861A
32
JP2009513567A
66
JP2011522802A
31
JP2011524416A
146
JP4787165B2
104
JPS63230697A
3

Sample Use Guides

In Vivo Use Guide
30-min infusion at a dose of 1.2 grams per m2 per day for 5 consecutive days
Route of Administration: Intravenous
In Vitro Use Guide
Human testicular germ cell tumour lines H 12.1 and 2102 EP were treated with ifosfamide at 50 mg kg-1 day-1.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:52:31 GMT 2025
Edited
by admin
on Wed Apr 02 09:52:31 GMT 2025
Record UNII
UM20QQM95Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOCYCLOPHOSPHAMIDE
Preferred Name English
IFOSFAMIDE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
Z4942
Code English
2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE, N,3-BIS(2-CHLOROETHYL)TETRAHYDRO-, 2-OXIDE
Systematic Name English
NSC-109724
Code English
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Systematic Name English
IFOSFAMIDE [USP-RS]
Common Name English
ifosfamide [INN]
Common Name English
IFOSFAMIDE [USAN]
Common Name English
IFOSFAMIDE [USP MONOGRAPH]
Common Name English
IFOSFAMIDE [EP IMPURITY]
Common Name English
MJF 9325
Code English
IFOSFAMIDE [MART.]
Common Name English
MJF-9325
Code English
IFOSFAMIDE [JAN]
Common Name English
Ifosfamide [WHO-DD]
Common Name English
Z-4942
Code English
IFOSFAMIDE [MI]
Common Name English
N,3-BIS(2-CHLOROETHYL)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE 2-OXIDE
Systematic Name English
IFOSFAMIDE [EP MONOGRAPH]
Common Name English
IFOSFAMIDE [HSDB]
Common Name English
ISOPHOSPHAMIDE [IARC]
Common Name English
IFOSFAMIDE [ORANGE BOOK]
Common Name English
IFOSFAMIDE [VANDF]
Common Name English
IFEX
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C697
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
WHO-VATC QL01AA06
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
WHO-ATC L01AA06
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
FDA ORPHAN DRUG 17786
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
NDF-RT N0000175558
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
NDF-RT N0000000236
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
LIVERTOX NBK548567
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
FDA ORPHAN DRUG 8585
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
Code System Code Type Description
PUBCHEM
3690
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
IUPHAR
7201
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
EVMPD
SUB08125MIG
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
DRUG BANK
DB01181
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
DRUG CENTRAL
1421
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
SMS_ID
100000083681
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
CAS
3778-73-2
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
FDA UNII
UM20QQM95Y
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
NCI_THESAURUS
C564
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
RS_ITEM_NUM
1336205
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
NSC
109724
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
CHEBI
5864
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID7020760
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
INN
2865
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
WIKIPEDIA
IFOSFAMIDE
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
MERCK INDEX
m6207
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY Merck Index
RXCUI
5657
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY RxNorm
MESH
D007069
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
LACTMED
Ifosfamide
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-237-3
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
HSDB
7023
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL1024
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
DAILYMED
UM20QQM95Y
Created by admin on Wed Apr 02 09:52:31 GMT 2025 , Edited by admin on Wed Apr 02 09:52:31 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of 3-DECHLOROETHYLIFOSFAMIDE
METABOLITE INACTIVE -> PARENT
Found in erythrocytes too
PLASMA
Structure of 3-DECHLOROETHYLIFOSFAMIDE
METABOLITE INACTIVE -> PARENT
Structure of CARBOXYIFOSFAMIDE
METABOLITE -> PARENT
Found in erythrocytes
PLASMA
Structure of PALIFOSFAMIDE
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of 2-DECHLOROETHYLIFOSFAMIDE
METABOLITE INACTIVE -> PARENT
Found in erythrocytes
PLASMA
Structure of 2,3-DIDECHLOROETHYL-IFOSFAMIDE
METABOLITE INACTIVE -> PARENT
Structure of 2-DECHLOROETHYLIFOSFAMIDE
METABOLITE INACTIVE -> PARENT
Structure of 4-KETOIFOSFAMIDE
METABOLITE -> PARENT
Found in erythrocytes too
PLASMA
Structure of ALDOIFOSFAMIDE
METABOLITE -> PARENT
In serum
Structure of ACROLEIN
METABOLITE TOXIC -> PARENT
MINOR
PLASMA
Structure of 2-CHLOROETHYLAMINE
METABOLITE -> PARENT
PLASMA
Structure of 4-HYDROXYIFOSFAMIDE
METABOLITE ACTIVE -> PRODRUG
labile intermediate
Related Record Type Details
Structure of 2-Aminoethanol
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BIS(3-((2-CHLOROETHYL)AMINO)PROPYL) DIHYDROGEN DIPHOSPHATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-CHLORO-N-(2-CHLOROETHYL)PROPAN-1-AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((2-CHLOROETHYL)AMINO)PROPYL DIHYDROGEN PHOSPHATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-(CHLOROETHYL)-2-CHLOROOXAAZAPHOSPHORINANE 2-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-CHLOROETHYLAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of 4-HYDROXYIFOSFAMIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966